73.34

0.07% 0.05

After Hours: 75.88 2.54 +3.46%

Halozyme Therapeutics Inc (HALO)

Overview News Price History Option Chain Financials Why HALO Down? Discussions Forecast

Halozyme Therapeutics Inc stock is traded at $73.34, with a volume of 1.83M. It is up +0.07% in the last 24 hours and up +0.26% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Previous Close:

$73.29

Open:

$73.96

24h Volume:

1.83M

Relative Volume:

0.83

Market Cap:

$8.58B

Revenue:

$947.36M

Net Income/Loss:

$392.47M

P/E Ratio:

24.28

EPS:

3.02

Net Cash Flow:

$392.71M

1W Performance:

-5.45%

1M Performance:

+0.26%

6M Performance:

+14.93%

1Y Performance:

+28.13%

1-Day Range:

$73.06

$74.93

1-Week Range:

$73.06

$78.33

52-Week Range:

$42.01

$79.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name

Halozyme Therapeutics Inc

Sector

Healthcare (1147)

Industry

Biotechnology (641)

Phone

(858) 794-8889

Address

12390 EL CAMINO REAL, SAN DIEGO, CA

Employee

350

Twitter

@halozymeinc

Next Earnings Date

2025-02-18

Latest SEC Filings

HALO's Discussions on Twitter

Compare HALO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HALO Halozyme Therapeutics Inc	73.34	8.57B	947.36M	392.47M	392.71M	3.02
VRTX Vertex Pharmaceuticals Inc	391.64	101.35B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	456.00	58.66B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	562.27	59.43B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	737.56	44.01B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	340.70	36.56B	3.81B	-644.79M	-669.77M	-6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-10-25	Resumed	Goldman	Neutral
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral
Feb-29-24	Initiated	TD Cowen	Outperform
Jul-24-23	Downgrade	Goldman	Buy → Neutral
Jul-24-23	Initiated	H.C. Wainwright	Buy
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Berenberg	Buy
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform
Dec-21-22	Resumed	Morgan Stanley	Overweight
Nov-28-22	Initiated	Wells Fargo	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-21-21	Reiterated	The Benchmark Company	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jul-01-20	Initiated	The Benchmark Company	Buy
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-08-20	Initiated	Goldman	Buy
Nov-05-19	Upgrade	Barclays	Underweight → Equal Weight
Oct-19-18	Resumed	Piper Jaffray	Neutral
May-11-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-24-18	Initiated	Goldman	Neutral
Oct-16-17	Reiterated	Piper Jaffray	Overweight
Jan-06-17	Downgrade	Citigroup	Buy → Neutral
Nov-03-16	Initiated	Deutsche Bank	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Nov-18-15	Initiated	Citigroup	Buy
Sep-22-15	Initiated	Barclays	Overweight
Jun-22-15	Reiterated	JP Morgan	Overweight
Mar-03-15	Reiterated	UBS	Buy
Feb-18-15	Reiterated	MLV & Co	Buy
Jan-08-15	Reiterated	MLV & Co	Buy

View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

Sep 30, 2025

Can volume confirm reversal in Halozyme Therapeutics Inc.Chart Signals & Precise Entry and Exit Recommendations - newser.com

Sep 30, 2025

Key metrics from Halozyme Therapeutics Inc.’s quarterly dataJuly 2025 Short Interest & Risk Controlled Daily Plans - newser.com

Sep 30, 2025

Halozyme: Royalty Harvest Now, Post-2027 Roadmap Still Thin (Maintain Hold) (NASDAQ:HALO) - Seeking Alpha

Sep 30, 2025

How geopolitical risks impact Halozyme Therapeutics Inc. (RV7) stockLong Setup & Weekly High Return Stock Opportunities - newser.com

Sep 30, 2025

Sep 29, 2025

How buybacks impact Halozyme Therapeutics Inc. stock valueJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - newser.com

Sep 29, 2025

Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - newser.com

Sep 29, 2025

Is it too late to sell Halozyme Therapeutics Inc.July 2025 Short Interest & Weekly Chart Analysis and Guides - newser.com

Sep 29, 2025

Institutional scanner results for Halozyme Therapeutics Inc.Market Growth Report & Smart Allocation Stock Tips - newser.com

Sep 29, 2025

Pattern recognition hints at Halozyme Therapeutics Inc. upsideM&A Rumor & Fast Entry Momentum Alerts - newser.com

Sep 29, 2025

Sep 27, 2025

What analysts say about Halozyme Therapeutics Inc stockPrice Momentum Alerts & Exceptional Return Stocks - earlytimes.in

Sep 27, 2025

HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN

Sep 27, 2025

Sep 26, 2025

Congress Asset Management Co. Sells 297,296 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat

Sep 26, 2025

Sep 25, 2025

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance

Sep 25, 2025